- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| METIS TECHBIO Aktie jetzt für 0€ handeln | |||||
| 04.09. | METiS TechBio revenue surges on licensing deal | 1 | China Daily | ||
| 25.08. | METIS TECHBIO-P Interim Loss Narrows to RMB153 Million | 3 | AASTOCKS | ||
| 25.08. | METIS TECHBIO-P (07666): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026 | - | HKEx | ||
| 12.08. | METIS TECHBIO-P (07666): DATE OF BOARD MEETING | 1 | HKEx | ||
| 04.08. | METIS TECHBIO-P (07666): (1) APPOINTMENT OF JOINT COMPANY SECRETARY; AND (2) WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES | - | HKEx | ||
| 03.08. | METIS TECHBIO-P (07666): VOLUNTARY ANNOUNCEMENT METIS TECHBIO ANNOUNCES COLLABORATION WITH HENGRUI PHARMACEUTICALS ON THE AITEM ARTIFICIAL INTELLIGENCE ... | 2 | HKEx | ||
| 31.07. | METIS TECHBIO-P (07666): (1) RESIGNATION OF CHIEF FINANCIAL OFFICER, BOARD SECRETARY AND JOINT COMPANY SECRETARY AND CHANGE OF PROCESS AGENT; (2) CHANGE ... | 2 | HKEx | ||
| 30.06. | Deerfield's Boulevard Bio pens $1.6B deal for trispecific TCE from China's Metis TechBio | 2 | FierceBiotech | ||
| 30.06. | Metis TechBio seals $1.62b global licensing deal with Boulevard Bio | 1 | China Daily | ||
| 30.06. | METiS TechBio vergibt Lizenz für Wirkstoffkandidaten in 1,6-Milliarden-Dollar-Deal | - | Investing.com Deutsch | ||
| 30.06. | METiS TechBio licenses drug candidate to Boulevard Bio for $1.6B | 3 | Investing.com | ||
| 30.06. | METIS TECHBIO-P (07666): VOLUNTARY ANNOUNCEMENT METIS TECHBIO ANNOUNCES A PRECLINICAL TCE LICENSING COLLABORATION WITH DEERFIELD OF UP TO US$1.6 BILLION | 2 | HKEx | ||
| 22.06. | METIS TECHBIO-P (07666): NOTIFICATION LETTER TO NON-REGISTERED HOLDERS OF AND REQUEST FORM - ARRANGEMENT OF ELECTRONIC DISSEMINATION OF CORPORATE COMMUNICATIONS | - | HKEx | ||
| 22.06. | METIS TECHBIO-P (07666): NOTIFICATION LETTER TO REGISTERED SHAREHOLDERS - ARRANGEMENT OF ELECTRONIC DISSEMINATION OF CORPORATE COMMUNICATIONS | 1 | HKEx | ||
| 12.06. | METIS TECHBIO-P (07666): CHANGE OF JOINT COMPANY SECRETARY AND AUTHORIZED REPRESENTATIVE AND WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF ... | 1 | HKEx | ||
| 10.06. | METIS TECHBIO-P (07666): NEXT DAY DISCLOSURE RETURN | 3 | HKEx | ||
| 10.06. | METIS TECHBIO-P (07666): ARTICLES OF ASSOCIATION | 1 | HKEx | ||
| 10.06. | METIS TECHBIO-P (07666): AMENDMENTS TO THE ARTICLES OF ASSOCIATION | - | HKEx | ||
| 05.06. | METIS TECHBIO-P (07666): FULL EXERCISE OF THE OVER-ALLOTMENT OPTION, STABILIZING ACTIONS AND END OF STABILIZATION PERIOD | 3 | HKEx | ||
| 26.05. | METIS TECHBIO-P (07666): CLARIFICATION ANNOUNCEMENT | 2 | HKEx |
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TEMPUS AI | 67,70 | -0,09 % | Tempus AI stock is soaring: does it have more upside to go? | ||
| MANNKIND | 3,073 | 0,00 % | MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management | Collaboration combines Rose Pharma investigational rapid-acting GLP-1 receptor agonist with MannKind's Technosphere- inhalation technologyMannKind to receive an equity interest and potential royalties... ► Artikel lesen | |
| NEOVACS | 0,310 | 0,00 % | XFRA NEW INSTRUMENTS AVAILABLE ON 23.06.2026 | The following instruments on XETRA do have their first trading 23.06.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 23.06.2026
Aktien
1 CNE100007CW0 Shenzen Xunce Technology... ► Artikel lesen | |
| HEMAB THERAPEUTICS | 41,190 | 0,00 % | Gubra A/S: Gubra collaboration partner Hemab announces first participant dosed in Phase 1 clinical trial of HMB-003, an investigational therapy for the management of heavy menstrual bleeding | Today, Gubra announced that its partner Hemab Therapeutics has dosed the first healthy volunteer in its Phase 1 clinical trial evaluating HMB-003, an investigational therapy for the management of heavy... ► Artikel lesen | |
| SCRIBE THERAPEUTICS | 33,000 | 0,00 % | Biotech Stocks At 52-Week Highs - Scribe Therapeutics Continues Rise After Nasdaq Debut, Royalty Pharma, Haemonetics, 10x Genomics, Labcorp Holdings | WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on August 20, 2026, driven by key catalysts such as new product launches and the prospective release of data from clinical... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 45,320 | 0,00 % | Biotech Options Buzz: UTHR, NMRA, EWTX | ||
| DYNE THERAPEUTICS | 17,110 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| SHATTUCK LABS | 6,010 | 0,00 % | Shattuck Labs, Inc.: Shattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business Highlights | - Phase 1 clinical trial results for SL-325 demonstrated a favorable safety profile, a potentially best-in-mechanism immunogenicity profile, and durable DR3 blockade of TL1A binding, potentially enabling... ► Artikel lesen | |
| ABSCI | 9,650 | 0,00 % | Absci auf Morgan Stanley Healthcare-Konferenz: KI-Plattform im klinischen Test | ||
| MBX BIOSCIENCES | 62,91 | 0,00 % | MBX Biosciences, Inc.: MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism | Pivotal Phase 3 oPTimize trial design builds on positive Phase 2 Avail results and durable one-year clinical benefit Global registrational trial to enroll approximately 160 adults with HP to support... ► Artikel lesen | |
| TYRA BIOSCIENCES | 25,730 | 0,00 % | Tyra Biosciences (TYRA) Dabogratinib Delivers 57% Complete Response Rate in Phase 2 Trial. Is Phase 3 Supported? | ||
| QIAGEN | 38,410 | -0,51 % | AKTIE IM FOKUS: Qiagen ziehen an - Magazinbericht schürt Übernahmefantasie | FRANKFURT (dpa-AFX) - Bei den Aktien von Qiagen hat am Donnerstag ein Magazinbericht die bereits bestehende Übernahmefantasie angeheizt. Die Aktien des Molekulardiagnostik-Unternehmens zogen am Mittag... ► Artikel lesen | |
| ELECTRA THERAPEUTICS | 13,500 | +1,89 % | Electra Therapeutics, Inc.: Electra Therapeutics Announces Pricing of Upsized $350.0 Million Initial Public Offering | SOUTH SAN FRANCISCO, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Electra Therapeutics, Inc., a late clinical-stage biopharmaceutical company focused on pioneering a new class of precision medicines... ► Artikel lesen | |
| CABALETTA BIO | 2,550 | 0,00 % | Cabaletta Bio, Inc. - 8-K, Current Report | ||
| PRAXIS PRECISION MEDICINES | 299,28 | +0,11 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen |
Das Unternehmen METIS TECHBIO CO LTD kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,207 (+12,18 %) liegt der Kurs bei 1,906 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu METIS TECHBIO CO LTD finden Sie auf Wallstreet Online.